Evidence map›Paper›PMID 37052656›Full record

ArticleEuropean biophysics journal : EBJ2023

Revealing the single-channel characteristics of OprD (OccAB1) porins from hospital strains of Acinetobacter baumannii.

Aliakbar Ebrahimi, Tuğçe Ergün, Özge Kaygusuz İzgördü, Cihan Darcan, Hüseyin Avci, Barçin Öztürk, Hatice Rahmet Güner, Hamed Ghorbanpoor, Fatma Doğan Güzel

Abstract read
PubMed Publisher
In one paragraph

Article in European biophysics journal : EBJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Phage Therapy forAntibiotics (Basel, Switzerland) · 2025
    Review
  3. Microbial membrane transport proteins and their biotechnological applications.World journal of microbiology & biotechnology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Aliakbar EbrahimiFaculty of Engineering and Natural Sciences, Department of Biomedical Engineering, Ankara Yildirim Beyazit University, Ankara, Turkey.ORCID http://orcid.org/0000-0001-6437-7796
Tuğçe ErgünFaculty of Engineering and Natural Sciences, Department of Biomedical Engineering, Ankara Yildirim Beyazit University, Ankara, Turkey.ORCID http://orcid.org/0000-0001-6266-3721
Özge Kaygusuz İzgördüBiotechnology Application and Research Center, Bilecik Şeyh Edebali University, Bilecik, Turkey.ORCID http://orcid.org/0000-0002-3652-4266
Cihan DarcanFaculty of Science and Literature, Department of Molecular Biology and Genetics, Bilecik Seyh Edebali University, Bilecik, Turkey.ORCID http://orcid.org/0000-0003-0205-3774
Hüseyin AvciCellular Therapy and Stem Cell Research Center and Translational Medicine Research and Clinical Center (ESTEM), Eskisehir Osmangazi University, Eskisehir, Turkey.ORCID http://orcid.org/0000-0002-2475-1963
Barçin ÖztürkFaculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Adnan Menderes University, Aydin, Turkey.ORCID http://orcid.org/0000-0003-3756-8276
Hatice Rahmet GünerFaculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara Yildirim Beyazit University, Ankara, Turkey.ORCID http://orcid.org/0000-0002-1029-1185
Hamed GhorbanpoorCellular Therapy and Stem Cell Research Center and Translational Medicine Research and Clinical Center (ESTEM), Eskisehir Osmangazi University, Eskisehir, Turkey.ORCID http://orcid.org/0000-0002-2665-8172
Fatma Doğan GüzelFaculty of Engineering and Natural Sciences, Department of Biomedical Engineering, Ankara Yildirim Beyazit University, Ankara, Turkey. fdogan@ybu.edu.tr.ORCID http://orcid.org/0000-0001-7200-4615
Ankara Yıldırım Beyazıt University · TRBilecik Şeyh Edebali Üniversitesi · TREskişehir Osmangazi University · TRAdnan Menderes University · TR

Funding

Türkiye Bilimsel ve Teknolojik Araştirma Kurumu 117S114
6 · The paper itself

Abstract

Nowadays, reports of antimicrobial resistance (AMR) against many antibiotics are increasing because of their misapplication. With this rise, there is a serious decrease in the discovery and development of new types of antibiotics amid an increase in multi-drug resistance. Unfermented Acinetobacter baumannii from gram-negative bacteria, which is one of the main causes of nosocomial infections and multi-drug resistance, has 4 main kinds of antibiotic resistance mechanism: inactivating antibiotics by enzymes, reduced numbers of porins and changing of their target or cellular functions due to mutations, and efflux pumps. In this study, characterization of the possible mutations in OprD (OccAB1) porins from hospital strains of A. baumannii were investigated using single channel electrophysiology and compared with the standard OprD isolated from wild type ATCC 19,606. For this aim, 5 A. baumannii bacteria samples were obtained from patients infected with A. baumannii, after which OprD porins were isolated from these A. baumannii strains. OprD porins were then inserted in an artificial lipid bilayer and the current-voltage curves were obtained using electrical recordings through a pair of Ag/AgCl electrodes. We observed that each porin has a characteristic conductance and single channel recording, which then leads to differences in channel diameter. Finally, the single channel data have been compared with the gene sequences of each porin. It was interesting to find out that each porin isolated has a unique porin diameter and decreased anion selectivity compared to the wild type.

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsHospitalsHumansPorinsAnti-Bacterial AgentsPorinsA. baumanniiOprDPorinsSingle-channel Electrophysiology

Identifiers

PMID37052656
OpenAlexW4365444057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.